Novavax

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. 

CEO
John C.s Jacobs
CEOJohn C.s Jacobs
Employees
952
Employees952
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1987
Founded1987
Employees
952
Employees952

NVAX Key Statistics

Market cap
1.14B
Market cap1.14B
Price-Earnings ratio
3.99
Price-Earnings ratio3.99
Dividend yield
Dividend yield
Average volume
4.90M
Average volume4.90M
High today
$7.18
High today$7.18
Low today
$6.88
Low today$6.88
Open price
$6.94
Open price$6.94
Volume
1.82M
Volume1.82M
52 Week high
$11.55
52 Week high$11.55
52 Week low
$5.01
52 Week low$5.01

Stock Snapshot

Novavax(NVAX) stock is priced at $7.04, giving the company a market capitalization of 1.14B. It carries a P/E multiple of 3.99.

On 2025-11-14, Novavax(NVAX) stock traded between a low of $6.88 and a high of $7.18. Shares are currently priced at $7.04, which is +2.4% above the low and -1.9% below the high.

Novavax(NVAX) shares are trading with a volume of 1.82M, against a daily average of 4.9M.

In the last year, Novavax(NVAX) shares hit a 52-week high of $11.55 and a 52-week low of $5.01.

In the last year, Novavax(NVAX) shares hit a 52-week high of $11.55 and a 52-week low of $5.01.

NVAX News

TipRanks 3d
Novavax price target lowered to $16 from $18 at B. Riley

B. Riley lowered the firm’s price target on Novavax (NVAX) to $16 from $18 and keeps a Buy rating on the shares following the Q3 report. The firm highlights the...

Simply Wall St 4d
Assessing Novavax Valuation Following Q3 Revenue Beat and Expanded Sanofi Collaboration

Novavax (NVAX) made headlines this week after reporting Q3 revenue that surpassed expectations, finalizing the transfer of U.S. marketing rights for its COVID-1...

Assessing Novavax Valuation Following Q3 Revenue Beat and Expanded Sanofi Collaboration
Simply Wall St 6d
Novavax Is Down 11.4% After Sanofi Vaccine Deal and Q3 Results - Has the Narrative Shifted?

In November 2025, Novavax completed the transfer of U.S. marketing authorization for its COVID-19 vaccine to Sanofi and reported third quarter results, which in...

Novavax Is Down 11.4% After Sanofi Vaccine Deal and Q3 Results - Has the Narrative Shifted?

Analyst ratings

56%

of 9 ratings
Buy
55.6%
Hold
22.2%
Sell
22.2%

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.